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Introduction: Familial breast cancer (fBC) is generally associated with an early age of diagnosis and a higher
frequency of disease among family members. Over the past two decades a number of genes have been identified
that are unequivocally associated with breast cancer (BC) risk but there remain a significant proportion of families
that cannot be accounted for by these genes. Copy number variants (CNVs) are a form of genetic variation yet to
be fully explored for their contribution to fBC. CNVs exert their effects by either being associated with whole or
partial gene deletions or duplications and by interrupting epigenetic patterning thereby contributing to disease
development. CNV analysis can also be used to identify new genes and loci which may be associated with disease risk.
Methods: The Affymetrix Cytogenetic Whole Genome 2.7 M (Cyto2.7 M) arrays were used to detect regions of
genomic re-arrangement in a cohort of 129 fBC BRCA1/BRCA2 mutation negative patients with a young age of
diagnosis (<50 years) compared to 40 unaffected healthy controls (>55 years of age).
Results: CNV analysis revealed the presence of 275 unique rearrangements that were not present in the control
population suggestive of their involvement in BC risk. Several CNVs were found that have been previously
reported as BC susceptibility genes. This included CNVs in RPA3, NBN (NBS1), MRE11A and CYP19A1 in five
unrelated fBC patients suggesting that these genes are involved in BC initiation and/or progression. Of special
interest was the identification of WWOX and FHIT rearrangements in three unrelated fBC patients.
Conclusions: This study has identified a number of CNVs that potentially contribute to BC initiation and/or
progression. The identification of CNVs that are associated with known tumour suppressor genes is of special
interest that warrants further larger studies to understand their precise role in fBC.
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Global cancer statistics identify BC as the most frequently
diagnosed cancer (23%) and leading cause of cancer re-
lated death (14%) in females [1]. Nearly 27% of these BCs
occur in a familial setting typically associated with an earl-
ier age of disease diagnosis and a higher frequency among
family members and is termed fBC [2,3]. It is estimated
that 5-10% of these families harbor germline mutations or
complex genomic changes that render inactive one of four
high penetrance genes (BRCA1, BRCA2, TP53 or PTEN)* Correspondence: Rodney.Scott@newcastle.edu.au
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unless otherwise stated.or moderate penetrance genes (CHEK2, ATM, BRIP1 and
PALB2) [2,4,5]. Associations have also been identified for
other genes in fBC including ATM, CASP8, CTLA4, NBN,
CYP19A1, TERT, and XRCC3 [6]. The most recent BC
meta-analysis has identified 41 loci and suggests that over
1000 loci may be involved in disease susceptibility [7]. The
identification of BRCA1 and BRCA2 as susceptibility
genes for BC and the more recent addition of PALB2,
BRIP1 and RAD51C [5] have focused attention on genes
associated with double strand break repair (DSBR). There
are at least 39 genes implicated in DSBR, all of which
could potentially be associated with BC risk. This is analo-
gous to DNA mismatch repair (MMR), where there are at
least 21 genes associated with this process, of which four
are now routinely assessed and more recently a fifth genel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plethora of information regarding genetic loci associated
with BC risk, for many fBC cases no genetic predispos-
ition has been identified. Outside the context of gene mu-
tations other mechanisms may be associated with disease
development including gene silencing as a result of epi-
genetic re-programming of BC susceptibility genes (analo-
gous to loss of EPCAM and the re-arrangement of the
epigenetic profile on chromosome 2, rendering MSH2 in-
active [10,11]), or mutations in genes not yet associated
with a predisposition to disease.
One type of genetic alteration that could account for sus-
ceptibility is genetic re-arrangements detected as CNVs.
CNVs represent a class of structural variation involving re-
gions of duplication or deletion of genomic material that
can encompass large stretches of genomic sequence ran-
ging from megabases (Mbs) to a few kilobases (Kb) in size.
As a consequence, CNVs can contribute to disease when
they incorporate functional gene sequence (coding and
promoter regions of genes) or exert more cryptic effects,
that could affect epigenetic regulation (methylation, micro-
RNA targets) and non-coding intronic gene sequences
[12-23]. Two reports have recently examined CNVs in as-
sociation with BRCA1/BRCA2 mutation negative fBC pa-
tients. The first of these has reported a greater abundance
of rare CNVs in fBC patients and suggest that rare CNVs
are likely to contain genetic factors associated with BC
predisposition, while the second report associated sev-
eral CNV markers with fBC risk and suggests their use
in disease risk assessment [24,25].
The detection of CNVs has historically relied upon the
use of DNA arrays, typically comprised of oligonucleotide
markers distributed across the whole genome. The reso-
lution of DNA arrays has increased to allow for the detec-
tion of genomic rearrangements as small as a few Kb in
size. In this study we used the Affymetrix Cyto2.7 M array
which provided the highest genomic coverage of any com-
mercially available microarray at the time of assay to assess
CNV variation in an fBC cohort. The Cyto2.7 M array con-
tains a combination of 400,000 single nucleotide polymor-
phisms (SNPs) and >2.1 million copy number probes
(average spacing 1395 base pairs (bp)) which together can
be used to accurately detect genomic rearrangements.
We conducted a patient-control analysis examining
129 fBC patients and 40 control subjects derived from
the same population to identify CNVs which could be
associated with the genetic basis of their disease. To date
this study represents one of the largest CNV studies of
BRCA1/BRCA2 mutation negative fBC patients.
Materials and methods
Samples
The study was approved by the University of Newcastle’s
Human Research Ethics Committee and the HunterNew England Human Research Ethics Committee. Gen-
omic DNAs were obtained from fBC patients who had
given informed consent for their DNA to be used for
studies into their disease and control DNA samples from
the Hunter Community Study (HCS) [26]. DNA was
extracted from whole blood by the salt precipitation
method [27].
A cohort of 129 patients clinically diagnosed with early-
onset fBC were used in this study. All patients had been
diagnosed with BC and were the first individual (proband)
of their family to seek genetic testing for mutations in
BRCA1/BRCA2. Mutation screening was performed using
Sanger Sequencing and Multiplex ligation-dependant
probe amplification (MLPA) analysis. No mutations were
identified in any of the patients (BRCA1/BRCA2 mutation
negative). The average patient age was calculated to be
<40.7 years. Genomic DNA from 40 controls [26] was also
utilized in this study. These were healthy (cancer free) in-
dividuals aged >55 years at the time of sample collection.
Genomic array preparation and data processing
The genomic DNA from 129 fBC patients and 40 controls
were processed on the Affymetrix Cyto2.7 M array consist-
ent with manufacturer’s protocols. CEL files were analysed
in Affymetrix, the Chromosome Analysis Suite (ChAS)
(Version CytoB-N1.2.0.232; r4280) using NetAffx Build
30.2 (Hg18) annotation. Quality control (QC) parameters
were optimized and validated using a training set of 20 ran-
domly selected samples. All samples were subject to a
series of quality cut-off measures: snpQC >1.1 (SNP probe
QC based off distances between the distribution of alleles
(AA, AB and BB) where larger differences are associated
with an increased ability to differentiate genotype; default),
mapdQC <0.27 (Median Absolute Pair-wise Difference;
CN probe QC based off a reference model; default)
and wavinessSd <0.1 (measure of standard deviation in
data waviness; the GC content across the genome corre-
lates with average probe intensities i.e. high GC probes are
brighter than low GC probes on average, creating waves
in the data). CNV regions were assessed according to call
confidence, probe count, size and by visual inspection for
distinction from normal CN state. Data was also visually
inspected to identify regions with low density of markers
(Additional file 1: Table S1) which were excluded across
all samples. Most thresholds were more stringent than de-
fault settings alone in an aim to minimize false-positive
CNVs being included in the analysis. CNV regions were
filtered across all samples using the following parameters:
>90% confidence, autosomes only and a minimum num-
ber of 24 probes. Using these parameters the limit of de-
tection was 9.65 Kb across all samples used in the current
study. This does not exclude the possibility of CNVs
smaller than this from contributing to disease in a propor-
tion of fBC patients.
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CNVs in fBC patients and controls were subject to a
series of comprehensive analyses which included: (1) in-
terrogation for CNVs residing in or ±100 Kb of 61 genes
(associated with DSBR, MMR and BC susceptibility) and
41 SNPs recently reported to be associated with BC risk
[6,7,28,29] (see Additional file 1: Tables S2 and S3); (2)
comparison of CNVs between fBC patients and controls
according to CN occurrence and distribution across the
genome; (3) identification of rare CNVs using the Database
of Genomic Variants (DGV); and (4) the identification of
genes associated with malignancy (non-specific) using the
Network of Cancer Genes (Version 3.0) and the Cancer
Gene Census (CGC; 15 March 2012) databases [30,31].
Associations (e.g. numbers and sizes of CNVs) were
statistically compared using a two tailed un-paired
t-test Graphpad Prism (Version 6) [32].
Validation of CNV results
CNV results were validated using pre-designed TaqMan
Copy Number (CN) Assays (Applied Biosystems). Up to
two CN assays were selected within the CNV region in-
dicated by the Cyto2.7 M array and CN assays, proximal
but external to the region were also selected as controls
(assay information summarized in Additional file 1:
Table S4). A total of 11 samples were run in triplicate
comprised of the sample(s) of interest, a calibrator (con-
trol) sample with known CN for the region of interest
and a no-template-control (NTC). Real-time PCR was
conducted according to manufacturer’s protocols using
10 ng of DNA sample in a final reaction volume of
20 μL. The assay was run on the real-time PCR machine
(Applied Biosystems 7500; SDS software Version v1.4)
according manufacturer’s protocols. The results were
exported to CopyCaller v2.0 software (Applied Biosys-
tems) for analysis.
Three CNVs were validated using this secondary inde-
pendent assay (Additional file 1: Table S5). The CNVs
included a CN gain and a CN loss in the WWOX gene
as well as a CN loss in the FHIT gene. Given the high
concordance between the CNV calling within the experi-
mental parameters set for this study and the independ-
ent copy number assays we considered that it was not
necessary to confirm all CNVs using a second independ-








Patients 129 310 2 2.40
Controls 40 104 2 2.60
p - - - 0.75Results
Array resolution and CNV detection
Analysis of Cyto2.7 M array data revealed a total of 414
CNVs in 169 individuals assessed in this study (Table 1).
CNVs detected ranged in size from 9.65 Kb to 1335.06
Kb. There was no difference in the average number of
CNVs identified in the patients versus the controls (p =
0.75). The average genomic burden of CNVs also did not
differ between patients (226.93 Kb) and controls (295.52
Kb), p = 0.30; or the average CNV size between patients
(76.22 Kb) and controls (106.57 Kb), s, p = 0.07.
Occurrence and distribution of CNVs in fBC patients
Overall 310 CNVs were identified in fBC patients of
which 35 also occurred in controls (Additional file 1:
Table S6). Since these regions were represented in the
control population they were removed from further ana-
lysis. Of the 275 CNVs unique to the patients (Add-
itional file 1: Table S7), 94 have was previously described
in the DGV and 39 spanned genomic regions that were
common to multiple patients (Table 2). Of these 11
CNVs (located on chromosomes 2, 3, 4, 6, 11, 14, 15, 17
and 18) were common to two patients; three were com-
mon to three patients (located on chromosomes 4, 5 and
19); and two were common to four patients (located on
chromosomes 3 and 18). Among these, three genomic
regions (located chromosomes 6, 11 and 19) were con-
sidered novel (not reported in the DGV) and likely to
represent regions of potential association with BC risk.
Of the CNVs unique to patients 160 (58.18%) encom-
passed genes. A CNV located in SUPT3H was also ex-
cluded from analysis as it was identified to be affected
by a re-arrangement in a control sample and considered
unlikely to be associated with disease risk. Therefore a
total of 159 genes were associated with a CNV were
identified as being unique to the fBC patients and repre-
sent genes potentially associated with disease. A total of
24 genes associated with 44 CNVs (gains, losses or both)
were identified in multiple individuals (as shown in
Table 3): 19 genes, including LAMB3, NBN, IL8 and
WWOX, were affected by a CNV in two individuals;
PIK3R5 and POU2F3 were affected by a CNV in three
individuals; ARHGEF12 and TMEM136 were affected by
a CNV in four individuals; and NAMPT was affected by











Table 2 Genomic regions associated with unique CNVs
identified in multiple patients
Type Chr Start (bp)* End (bp)* Size (Kb) Probes
2 CNV gains
Gain 2 13,119,088 13,199,687 80.6 48
Gain 2 13,135,013 13,199,687 64.7 43
Gain 2 82,055,473 82,163,764 108.3 85
Gain 2 82,056,404 82,168,370 112.0 89
Gain 3 958,296 1,012,953 54.7 33
Gain 3 975,908 1,032,700 56.8 29
Gain 6 27,738,385 27,764,062 25.7 26
Gain 6 27,742,403 27,770,374 28.0 24
Gain 15 79,783,294 79,876,946 93.7 77
Gain 15 79,795,446 79,876,343 80.9 70
Gain 17 21,503,478 21,648,413 144.9 25
Gain 17 21,503,478 21,650,626 147.2 26
3 CNV gains
Gain 4 25,672,202 25,703,024 30.8 31
Gain 4 25,678,621 25,710,178 31.6 32
Gain 4 25,680,434 25,710,412 30.0 31
Gain 5 59,749,693 59,807,906 58.2 51
Gain 5 59,749,693 59,807,906 58.2 51
Gain 5 59,749,693 59,810,944 61.3 52
Gain 19 36,911,234 36,939,557 28.3 36
Gain 19 36,918,927 36,940,929 22.0 32
Gain 19 36,918,927 36,944,555 25.6 36
2 CNV losses
Loss 11 95,844,428 95,917,476 73.1 54
Loss 11 95,844,428 95,917,476 73.1 54
Loss 14 44,229,915 44,294,996 65.1 53
Loss 14 44,229,915 44,294,996 65.1 53
Loss 17 19,439,549 19,476,055 36.5 28
Loss 17 19,439,549 19,476,055 36.5 28
Loss 18 1,714,779 1,828,901 114.1 109
Loss 18 1,714,779 1,828,901 114.1 109
4 CNV losses
Loss 3 166,523,809 166,565,186 41.4 39
Loss 3 166,523,809 166,565,186 41.4 39
Loss 3 166,523,809 166,566,558 42.8 40
Loss 3 166,525,250 166,565,186 39.9 38
Loss 18 1,894,368 1,974,284 79.9 63
Loss 18 1,894,368 1,974,284 79.9 63
Loss 18 1,894,368 1,974,284 79.9 63
Loss 18 1,894,368 1,974,284 79.9 63
2 CNV gain and loss
Gain 4 160,917,340 161,068,954 151.6 119
Loss 4 160,983,513 161,011,918 28.4 29
Probes = number of markers within a CNV segment.
*set at first and last marker associated with the respective CNV.
Table 3 Genes associated with unique CNVs identified
across multiple patients
Number of Patients Gene Loci











Both 2 CNTN4 3p26.3
2 IMMP2L 7q31.1
2 WWOX 16q23.1
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There were 95 rare CNVs identified in 42 of the fBC pa-
tients. Of these 70 were associated with 78 genes and
were found in 27 patients. Out of the 78 genes SUPT3H
was excluded from further analysis as it was identified in
a healthy control subject. Ten genes that were disrupted
due to the presence of a CNV had previously been asso-
ciated with cancer [30,31] including ARHGAP26, ARH-
GEF12, CARD11, CPD, FAM135B, TSHR, MLLT11, PTK2B,
RHOH and FHIT (Table 4). The remaining CNVs affecting
67 genes were unique and have not previously been associ-
ated with malignancy (listed in Additional file 1: Table S8).
These genes potentially represent new candidates that re-
quire further investigation.
Genomic changes involving BC susceptibility genes or the
recently identified BC susceptibility loci
There are at least 61 genes including those involved in
DNA DSBR and MMR that could potentially contribute
to fBC [6,7,28,29]. CNV data for the 129 fBC patients and
40 controls was screened for genomic re-arrangements
within or ±100 Kb either side of these 61 genes. Five
Table 4 Results for the ten CNVs associated with seven
patients which affect genes previously associated with
cancer
Genes Dx Type Chr Start (bp) End (bp) Size (Kb)
FHIT 22 Loss 3 60,494,885 60,632,282 137.4
CARD11 37 Gain 7 2,946,394 2,996,375 50
FAM135B 38 Gain 8 139,259,837 139,306,535 46.7
ARHGEF12 51 Gain 11 119,697,081 119,723,342 26.3
TSHR ~49 Gain 14 80,659,512 80,669,166 9.7
MLLT11 46 Gain 1 149,289,549 149307059 17.5
CPD Gain 17 25,700,671 25,756,973 56.3
RHOH 28 Gain 4 39,864,888 39,888,181 23.3
ARHGAP26 Gain 5 142,147,309 142,174,652 27.3
PTK2B Gain 8 27,237,115 27,333,842 96.7
Gene, age of patient diagnosis (Dx), CNV type (gain or loss), location
(chromosome, start and end) and CNV size are indicated.
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within or in the vicinity of four genes (Table 5): one within
RPA3 gene; two within the NBN gene; one 55.7 Kb up-
stream of the MRE11A gene and one other 89.2 Kb up-
stream of the CYP19A1 gene. All gains are predicted to
result in disruption of the respective genes’ coding se-
quence (via the insertion of additional genomic material
which is expected to result in loss of function). With re-
spect to the NBN gene a CNV loss was also identified in a
control residing in a region located 52.6 Kb downstream
of the gene but did not appear to be associated with dis-
ruption of the coding sequence.
No CNVs were identified that were located in the
same 41 genomic regions that have recently been re-
ported as BC susceptibility loci [7].
The identification of a CNV that involved WWOX in
two unrelated patients (see Table 6, Figures 1 and 2) was
of interest as this gene is located in a fragile site (FRA16D)
associated with cancer development and has been shown
to interact with TP53 and ACK1 [33] and has recently
been reported to be involved in breast carcinogenesis
[34,35]. Together, this suggests that loss of function of
WWOX could potentially be involved in BC susceptibility.





55.7 Kb upstream MRE11A Gain
89.2 Kb upstream CYP19A1 Gain
Control 52.6 Kb downstream NBN Loss
CNV location (chromosome, start bp and end bp), size (Kb) and type; as well as thedisrupt the coding sequence of the gene via the insertion
of additional genomic material whereas the other patient
had a CNV loss that is expected to result in loss of func-
tion. Both of these changes were confirmed using an inde-
pendent CN assay (see Additional file 1: Table S5). A
number of recent reports have also correlated BC devel-
opment with changes in the FHIT gene which similarly to
WWOX is located in a fragile site (FRA3B) and has again
been linked to tumour development [36-43]. CNV analysis
revealed a CN loss that encompassed FHIT (Table 6 and
Figure 3) which was confirmed using an independent
assay (Additional file 1: Table S5).
Discussion
The association between CNVs and fBC is yet to be fully
defined. In this study we provide evidence that CNVs
are a potential explanation for small but significant
number of fBC patients who do not harbour germline
mutations in known susceptibility genes.
Genomic resolution provided by microarray technol-
ogy has increased significantly allowing for the discovery
of ever smaller CNVs. The resolution of the array used
in this study was limited to the identification of CNVs
greater than 9.65 Kb in size, and hence we cannot rule
out the potential involvement of smaller CNVs in the
aetiology of fBC. There have been a number of technical
issues associated with the identification of CNVs that
have compounded the difficulties in assessing the role of
genomic rearrangements in disease. Different array plat-
forms, software algorithms, batch effects and population
stratification influence the accuracy of calls made to and
comparisons of CNV data [44-46]. To help in reducing
the influence of these effects a set of 40 older population
controls was used as the basis to differentiate between
CNVs associated with breast cancer and uninformative
controls. All samples (both cases and controls) were
processed on one platform and analysed using the same
analysis software and experimental parameters. Com-
parison between the number and size of CNVs between
patients and controls did not reveal any significant dif-
ferences between cohorts. It is important to note the
limited number of controls utilized in the current studyosses within ±100 Kb the 61 genes associated with BC risk
Chr Start (bp) End (bp) Size (Kb)
7 7,670,435 7,697,631 27.2
8 91,048,149 91,070,004 21.9
8 91,050,795 91,088,236 37.4
11 93,922,391 93,960,356 38.0
15 49,507,272 49,579,058 71.8
8 90,913,791 90,962,106 48.3
gene affected by the variant are indicated.
Table 6 CNVs associated with fragile site FRA16D and FRA3B
Chr Start (bp) End (bp) Size (Kb) Gene Probes DGV
16 76,684,338 76,929,109 244.8 WWOX 222 Reported
16 76,947,909 77,009,160 61.3 WWOX 69 Reported
3 60,494,885 60,632,282 137.4 FHIT 158
CNV location (chromosome, start bp and end bp) and size (Kb); as well as the
confidence score associated with CNV call, the gene affected by the variant,
the number of probes used to call the CNV and if the variant has previously
been reported in the DGV.
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note that despite this potential limitation, our observa-
tions are consistent with two previous reports on fBC
(68 patients and 100 controls) and BRCA1-associated
ovarian cancer (84 patients and 47 controls) [24,47].
We also identified 67 genes associated with novel
CNVs that have yet to be linked with BC risk. It is inter-
esting to note that many of these have been implicated
in biological processes involving metabolism and bio-
logical regulation [48]. This provides the basis for fur-
ther investigation into expanding the number of genes
involved in BC development.
Our study has identified CNVs in close proximity to a
number of genes previously associated with BC risk in a
fBC cohort: ARHGEF12 has been proposed to be a can-
didate tumour suppressor gene in BC whereby its underA
B
Figure 1 CNV results for WWOX duplication in fBC patient. (A) CNV pr
including the genomic state (where 0 = the normal two copies and +1 = o
with respect to the CN assays used in validating the variant; and (C) TaqMa
Hs03934141_cn: note the normal two copies of this region identified in the
and the CN range bars associated with the three technical replicates usedexpression (typically as a result of genomic loss) has
been observed in BC cell lines and where re-induction
of the gene resulted in reduced cell proliferation and col-
ony formation [49]; Laminin 5 (LN5) genes (including
LAMB3) have been shown to exhibit reduced expression
as a result of epigenetic inactivation in 65% of BC cell
lines [50]; NBN has been recently reported to be associ-
ated with BC risk [6]; and NAMPT has been shown to
modify the effects of PARP inhibitors used in the treat-
ment of triple-negative BCs suggesting the potential for
a combination of NAMPT and PARP inhibitors in the
treatment of this disease [51].
Of all the genes affected by a CNV identified in more
than one patient, the most frequently reported for BC de-
velopment has been aberrations in WWOX. This tumour
suppressor gene has been shown to be critical for normal
breast development [34] with mutations in exons 4 to 9
frequently observed in BC tumours [35]. High expression
of WWOX has been shown to be beneficial in association
with tamoxifen treatment [52]. We further evaluated two
unrelated fBC patients, one harbouring a CNV gain and
the other a CNV loss. In both cases, the genomic rear-
rangements are predicted to reduce WWOX expression
and thereby contribute to disease risk. Our results suggest
that inherited deficiencies in WWOX are associated with
disease but we could not demonstrate that these alter-
ations were transmitted across generations due to ethicalC
ofile from Cyto2.7 M array data defining the region of duplication
ne extra copy; (B) Location of the duplication within the gene and
n CN Validation assay showing the duplication represented by
control, confirmation of the aberrant three copies in the fBC patient
to validate the CNVs.
AB
C
Figure 2 CNV results for WWOX deletion in fBC patient. (A) CNV profile from Cyto2.7 M array data defining the region of deletion including
the genomic state (where 0 = the normal two copies and -1 = one less copy; (B) Location of the deletion within the gene and with respect to
the CN assays used in validating the variant; and (C) TaqMan CN Validation assay showing the deletion represented by Hs03945201_cn: note the
normal two copies of this region identified in the control, confirmation of the aberrant one copy in the fBC patient and the CN range bars




Figure 3 CNV results for FHIT deletion in fBC patient. (A) CNV profile from Cyto2.7 M array data defining the region of deletion including the
genomic state (where 0 = the normal two copies and -1 = one less copy; (B) Location of the deletion within the gene and with respect to the CN
assays used in validating the variant; and (C) TaqMan CN Validation assay showing the deletion represented by Hs06656584_cn: note the normal
two copies of this region identified in the control, confirmation of the aberrant one copy in the fBC patient and the CN range bars associated
with the three technical replicates used to validate the CNVs.
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we have observed variants occurring in this gene (>1.55%)
suggests that they may account for a significant propor-
tion of BRCA1/BRCA2 mutation negative fBC patients.
Functional studies are required to determine the precise
effect of these variants in the alteration ofWWOX expres-
sion and BC development.
The identification of CNVs in close proximity to BC
susceptibility genes and loci that either contributes to
disease development directly or via more cryptic means
expands our understanding of their contribution to dis-
ease risk in fBC. Our study identified CNVs residing in
three genes RPA3, NBN, MRE11A and CYP19A1 which
supports their involvement in BC [6,28,29,53-56]. Given
the predicted disruption of RPA3, NBN, MRE11A and
CYP19A1 it is likely that these variants are associated
with disease.
Within our fBC cases we identified several genes within
or in close proximity to rare CNVs which have previously
been associated with BC: the putative oncogene MLLT11
(aka AF1Q) has been reported to be over expressed in a BC
cell line affecting invasive and metastatic potential [57,58];
while PTK2B has been shown to be the most frequently
lost kinase in sporadic BC tumours and is suggested to
contribute to the disease phenotype [59]. Of the rare CNVs
associated with malignancy, the gene most frequently asso-
ciated with BC development is the tumour suppressor
FHIT. FHIT has been reported multiple times to be
genetically and epigenetically modified in breast tu-
mours [36-41]; its expression has been reported to be
protective against HER2-driven breast tumour devel-
opment [42]; whereas reduced expression is associated
with poor prognosis [43]. A germline intronic deletion
in FHIT has also been identified in a pancreatic cancer
study [60]. Given that we have found a constitutional
CNV in FHIT we suggest that variants in this gene
could also account for a fraction of fBC patients. As
we were unable to obtain other family members it re-
mains to be seen if these genomic re-arrangements
confer significant disease risk in a family setting rather
than being associated with disease progression.
A recent report using 68 patient and 100 controls sug-
gested that rare CNVs may contribute to disease in a
small proportion of fBC patients [24]. In contrast to our
findings this study reported significantly lower percent-
ages of rare CNVs in fBC patients (4%) compared to the
level observed in the current study (30.65%) [24]. The
discrepancies in these findings are most likely to be re-
lated to differences in sample populations, the type of
array used (variation in array coverage and density), as
well as the algorithm used by the analysis software
[44-46]. These findings reinforce the need to obtain lar-
ger cohorts of patients and controls to better understand
the contribution of CNVs to breast cancer development.Conclusions
This study has revealed that there are a number of CNVs
which may contribute to the development of fBC. Sev-
eral previously reported BC susceptibility genes that in-
clude RPA3, NBN, MRE11A and CYP19A1 were found
to be influenced by the presence of a CNV. It was also
revealed by this investigation that three unrelated fBC pa-
tients harboured CNVs in WWOX and FHIT. We propose
that variants in these genes may account for disease in a
significant proportion of fBC patients. Overall the results
of this study provide further grounds for further investiga-
tion into the presence of CNVs in larger series of fBC pa-
tients who do not harbour changes in known breast
cancer susceptibility genes.Additional file
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